4/11
08:22 pm
arct
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate [Yahoo! Finance]
Medium
Report
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate [Yahoo! Finance]
4/10
12:48 pm
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Medium
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
4/10
08:10 am
arct
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 [Yahoo! Finance]
Medium
Report
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 [Yahoo! Finance]
4/10
08:00 am
arct
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
High
Report
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
3/21
05:36 pm
arct
CSL initiated with an Overweight at Morgan Stanley [Yahoo! Finance]
Low
Report
CSL initiated with an Overweight at Morgan Stanley [Yahoo! Finance]
3/10
11:01 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $74.00 to $68.00. They now have a "buy" rating on the stock.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $74.00 to $68.00. They now have a "buy" rating on the stock.
3/10
08:12 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) was given a new $48.00 price target on by analysts at BTIG Research.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) was given a new $48.00 price target on by analysts at BTIG Research.
3/7
12:54 pm
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at HC Wainwright from $63.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at HC Wainwright from $63.00 to $60.00. They now have a "buy" rating on the stock.
3/7
11:23 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/7
10:27 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Wells Fargo & Company from $58.00 to $50.00. They now have an "overweight" rating on the stock.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Wells Fargo & Company from $58.00 to $50.00. They now have an "overweight" rating on the stock.
3/6
04:42 pm
arct
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress [Yahoo! Finance]
3/6
04:01 pm
arct
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Medium
Report
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
3/5
07:07 pm
arct
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
3/5
04:30 pm
arct
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Low
Report
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
2/24
04:24 pm
arct
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 [Yahoo! Finance]
Medium
Report
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 [Yahoo! Finance]
2/24
04:01 pm
arct
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
Medium
Report
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
2/14
01:28 pm
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.
2/14
08:30 am
arct
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Medium
Report
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
2/14
08:27 am
arct
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine [Yahoo! Finance]
Medium
Report
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine [Yahoo! Finance]
2/14
08:00 am
arct
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Medium
Report
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
2/4
09:04 am
arct
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate [Yahoo! Finance]
2/4
08:30 am
arct
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Low
Report
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
1/31
03:00 am
arct
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
Low
Report
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
1/30
04:01 pm
arct
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Low
Report
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
1/28
08:00 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $41.00 price target on the stock.
Medium
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $41.00 price target on the stock.